Nevertheless, guidelines advocate a tailored approach to target identification in HR+/HER2-negative ABC, focusing on tumor and patient factors to optimize treatment selection and guide clinicians in sequencing therapies [2,16,17,18]. This evidence concerns the gene ERBB2 and neoplasm.